Chembio Diagnostics Announces Expansion Of Direct-to-Consumer Commercial Channel
Chembio Diagnostics, Inc. (Chembio) (Nasdaq: CEMI), a leading point-of-care diagnostic company focused on infectious diseases, today announced the launch of its direct-to-consumer commercial channel for the
Chembio Diagnostics’s Return On Capital Employed Overview
According to data from Benzinga Pro, during Q1, Chembio Diagnostics's (NASDAQ:CEMI) reported sales totaled $18.82 million. Despite a 37.09% increase in earnings, the company posted a loss of $8.79 million.
110 Biggest Movers From Friday
Gainers
ShiftPixy, Inc. (NASDAQ: PIXY) shares jumped 154.9% to close at $0.51. ShiftPixy reported board approval special dividend to shareholders in form of common shares of Industrial Human Capital.
Earnings Scheduled For May 5, 2022
Companies Reporting Before The Bell
• Mirum Pharmaceuticals (NASDAQ:MIRM) is expected to report quarterly loss at $1.34 per share on revenue of $8.46 million.
12 Health Care Stocks Moving In Friday’s After-Market Session
Gainers
Ocular Therapeutix (NASDAQ:OCUL) shares moved upwards by 12.3% to $4.01 during Friday's after-market session. The company's market cap stands at $307.7 million.
Stocks That Hit 52-Week Lows On Wednesday
Wednesday's session saw 784 companies set new 52-week lows.
Stocks That Hit 52-Week Lows On Tuesday
During Tuesday, 581 stocks hit new 52-week lows.
Interesting Highlights From Today's 52-Week Lows
Meta Platforms (NASDAQ:FB) was the biggest company on a market cap basis to set a new 52-week low.
Looking Into Chembio Diagnostics’s Return On Capital Employed
Chembio Diagnostics (NASDAQ:CEMI) brought in sales totaling $20.57 million during Q4 according to data provided by Benzinga Pro. However, earnings decreased 119.5%, resulting in a loss of $13.97 million.